@Nightli68397147@ectorjaime@Claudiashein Por cierto, no confundas servicio social con posgrado, una gran cantidad de posgrados tienen beca sin importar la carrera
Ordering a #rheumatoid factor (RF) test in a patient with no suspected rheumatoid #arthritis (RA) or other autoimmune disorder is problematic. Although the name "rheumatoid" leads many doctors to associate it with RA, RF testing is not a suitable screening technique for RA in the general population and can be positive in several other chronic conditions (autoimmune and other types, especially infectious), as well as in the normal general population (5% in healthy 50-year olds and 10-25% in healthy 70-year olds). A significant amount of time is wasted in rheumatology clinics due to positive RF results ordered for diseases with which it is not even associated.
Systematic review of MTX use in RA-ILD.
šNot associated with ILD development (9 studies) and ILD progression (5 studies)
šAssociated with better survival (1 study) and acute exacerbations (1 study)
š¤Time to use MTX appropriately
https://t.co/OGpLF7X3Cd
š Denosumab:
-Denosumab is a monoclonal antibody that inhibits RANKL, a key protein needed for osteoclast formation ā ā bone resorption and ā bone density.
š Clinical Uses:
It can be used for
ā¢Postmenopausal osteoporosis (to reduce fractures)
ā¢Bone loss due to androgen deprivation (men with prostate cancer) or aromatase inhibitors (breast cancer)
ā¢Prevention of skeletal-related events in bone metastases
ā¢Giant cell tumor of bone
ā¢Hypercalcemia of malignancy refractory to bisphosphonates
The dose and frequency as well as the product determine the conditions that can be treated.āØ
āļø Mechanism of Action:
ā¢Binds RANKL, preventing it from activating RANK on osteoclasts ā
𦓠ā Osteoclast activity
𦓠ā Bone breakdown
𦓠ā Bone mineral density
ā ļø Key Safety Points:
ā¢š§Ŗ Check serum calcium, phosphorus, and magnesium before each dose
ā¢š« Contraindicated in hypocalcemia ā correct before use
ā¢š¦· Risk of osteonecrosis of the jaw (ONJ) ā maintain good oral hygiene
ā¢ā” May cause hypocalcemia, skin infections, or rebound fractures if stopped abruptly
š Clinical Tips:
ā¢If stopping denosumab ā switch to bisphosphonate (to prevent rebound bone loss & fractures)
ā¢Ensure adequate calcium (ā„1000 mg/day) + vitamin D (ā„400 IU/day) intake
š§ Mnemonic: āDENOā
D ā Donāt stop suddenly (rebound fractures)
E ā Ensure calcium & vitamin D
N ā Not for hypocalcemia
O ā Osteonecrosis of jaw (rare but serious